Cegolon Luca, Patriarca Emilia, Larese Filon Francesca
Department of Medical, Surgical & Health Sciences, University of Trieste, 34128 Trieste, Italy.
Public Health Unit, University Health Agency Giuliano-Isontina (ASUGI), 34128 Trieste, Italy.
Vaccines (Basel). 2025 Jun 9;13(6):622. doi: 10.3390/vaccines13060622.
: Thimerosal has been widely used as a preservative to prevent microbial growth in medications and vaccines. However, in 1999 its removal from vaccine formulations was called for due to concerns about its potential side effects on humans, with subsequent reduced sensitizations at patch tests. The present multi-center study investigated the epidemiological, occupational and temporal pattern of sensitization to Thimerosal in North-Eastern Italy during 1997-2023 and associated factors. : Due to variability in patch testing and positive reactions by the centers, this study was broken down by three periods: 1997-2004 (including all centers but Trieste); 1997-2015 (considering only Padua and Pordenone); and 2010-2023 (considering only Trieste and Pordenone). Multiple logistic regression was used to investigate prevalence of sensitization to Thimerosal and associated factors. Results were expressed as adjusted odds ratio (aOR) with 95% confidence intervals (95%CI). : Prevalence of positive patch test reactions to Thimerosal decreased from (8.13%) in 1997 to 0.95% in 2023 across all centers combined. Prevalence of positivity to Thimerosal was 9.49% during 1997-2004 (in all centers yet excluding Trieste), 8.41% during 1997-2015 (considering only Padua and Pordenone) and 4.01% during 2010-2023 (considering only Trieste and Pordenone). A significantly decreasing trend of Thimerosal sensitization was observed during 1997-2015 (aOR = 0.94; 95%CI: 0.92; 0.95). Regardless of the study period, sensitization to Thimerosal was consistently and significantly higher among health care workers (HCWs) and in patients born during 1981-1990. : The significantly decreasing prevalence of sensitization to Thimerosal over time likely reflected removal policies from vaccines and medications after 1999. Likewise, the higher prevalence of patch test reactions in patients born during 1981-1990 may mirror the widespread presence of this hapten in vaccines and medications in the 1980ies. Moreover, the increased prevalence of patch test reactions positive to Thimerosal in HCWs probably reflected higher influenza vaccination uptake in this group compared to other occupational categories. Positive patch test reactions to Thimerosal after 2000 were likely clinically irrelevant though.
硫柳汞已被广泛用作防腐剂,以防止药物和疫苗中的微生物生长。然而,1999年,由于担心其对人类的潜在副作用,人们呼吁从疫苗配方中去除硫柳汞,随后斑贴试验中的致敏反应有所减少。本多中心研究调查了1997年至2023年意大利东北部对硫柳汞致敏的流行病学、职业和时间模式以及相关因素。
由于各中心在斑贴试验和阳性反应方面存在差异,本研究分为三个时期:1997 - 2004年(包括除的里雅斯特以外的所有中心);1997 - 2015年(仅考虑帕多瓦和波代诺内);以及2010 - 2023年(仅考虑的里雅斯特和波代诺内)。采用多因素逻辑回归分析来研究对硫柳汞致敏的患病率及相关因素。结果以调整后的优势比(aOR)及95%置信区间(95%CI)表示。
所有中心综合来看,对硫柳汞斑贴试验阳性反应的患病率从1997年的8.13%降至2023年的0.95%。1997 - 2004年(所有中心但不包括的里雅斯特)对硫柳汞阳性反应的患病率为9.49%,1997 - 2015年(仅考虑帕多瓦和波代诺内)为8.41%,2010 - 2023年(仅考虑的里雅斯特和波代诺内)为4.01%。在1997 - 2015年期间观察到硫柳汞致敏呈显著下降趋势(aOR = 0.94;95%CI:0.92;0.95)。无论研究时期如何,医护人员(HCWs)以及1981 - 1990年出生的患者中对硫柳汞的致敏率始终显著更高。
随着时间推移,对硫柳汞致敏率显著下降可能反映了1999年后疫苗和药物中去除硫柳汞的政策。同样,1981 - 1990年出生的患者中斑贴试验反应较高的患病率可能反映了20世纪80年代这种半抗原在疫苗和药物中的广泛存在。此外,医护人员中对硫柳汞斑贴试验反应阳性率增加可能反映了该群体与其他职业类别相比流感疫苗接种率更高。不过,2000年后对硫柳汞斑贴试验阳性反应在临床上可能无关紧要。